logo
Plus   Neg
Share
Email

Novartis: Cosentyx Phase III Trial Meets Primary Endpoint At Week 16

Novartis (NVS) reported that the PREVENT trial evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis met its primary endpoint of ASAS40 at Week 16, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. The trial also met all secondary endpoints. The safety profile was consistent with the previous trials.

Novartis said these data add to the existing evidence supporting Cosentyx as a long-lasting treatment. The company anticipates 52-week data from the PREVENT study, to support FDA submission, later in the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT